A5001762900- Gastric Cancer Management and Outcomes
- Esophageal and GI Pathology
- Colorectal Cancer Surgical Treatments
- Gallbladder and Bile Duct Disorders
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Biliary and Gastrointestinal Fistulas
- Foreign Body Medical Cases
- Colorectal Cancer Screening and Detection
- Intestinal and Peritoneal Adhesions
- Abdominal Surgery and Complications
- Inflammatory Bowel Disease
- Gastroesophageal reflux and treatments
- Hernia repair and management
- Abdominal vascular conditions and treatments
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Helicobacter pylori-related gastroenterology studies
- Esophageal Cancer Research and Treatment
- Eosinophilic Esophagitis
- TGF-β signaling in diseases
- Ocular Diseases and Behçet’s Syndrome
- Gastrointestinal Bleeding Diagnosis and Treatment
- Pain Management and Opioid Use
- Pancreatitis Pathology and Treatment
Nagoya Memorial Hospital
2019-2024
Chukyo Hospital
2012-2020
Japan Community Healthcare Organization
2016-2018
National Institute of Diabetes and Digestive and Kidney Diseases
2018
ProQuest (United States)
2018
Gifu Prefectural Tajimi Hospital
2007-2009
Nagoya City University
2005-2007
University of Arizona
2007
Kogakuin University
2006
Tokyo Medical and Dental University Hospital
2004
Transpapillary bile duct brushing cytology and/or forceps biopsy was performed in the presence of an indwelling guidewire patients with biliary stricture, and treatment time, overall diagnosis rate, rate each disease, complications, influences on subsequent drainage were investigated.After endoscopic retrograde cholangiography, performed, followed by biopsy. In obstructive jaundice, (EBD) subsequently performed. To investigate EBD, who underwent EBD plastic stent compared alone.The samples...
ABSTRACT Background. Gastric atrophy induced by Helicobacter pylori is thought to predispose patients noncardiac gastric cancer development. However, the host genetic factors that influence progression of have not been elucidated. In this study, we examined effects cytokine polymorphisms on H. ‐induced atrophy. Methods. Blood samples were taken from 454 Japanese subjects. The interleukin‐2 (IL‐2; T‐330G), IL‐4 (C‐33T), and IL‐13 (C‐1111T) genotyped polymerase chain reaction with confronting...
We aimed to clarify the clinical benefits of using 8-mm versus 10-mm diameter self-expandable metallic stent (SEMS) in bilateral endoscopic stent-in-stent (SIS) deployment for malignant hilar biliary obstruction (MHBO).A total 72 consecutive patients with MHBO treated by SIS were enrolled. The and SEMSs used 37 (8-mm group) 35 (10-mm group), respectively. retrospectively compared technical success, functional complications, successful re-intervention, time recurrent (RBO) survival between...
Background Our recent prospective study found equivalent accuracy of magnifying chromoendoscopy (MC) and endoscopic ultrasonography (EUS) for diagnosing the invasion depth colorectal cancer (CRC); however, whether these tools show diagnostic differences in categories such as tumor size morphology remains unclear. Hence, we conducted detailed subset analysis data. Methods In this multicenter, prospective, comparative trial, a total 70 patients with early, flat CRC were enrolled from February...
Abstract Background and Aim Endoscopic biliary duodenal stenting (DS; double stenting) is widely accepted as a palliation therapy for malignant bilioduodenal obstruction. The aim of the current study was to investigate patency adverse events stents in patients with DS. Methods Patients who underwent DS from April 2004 March 2017 were analyzed retrospectively regard clinical outcomes predictive factors recurrent obstruction (recurrent [RBO] [RDO]). Results A total 109 consecutive enrolled....
Self-expandable metallic stent placement is accepted as palliative therapy for advanced gastric cancer with outlet obstruction, but data are lacking chemotherapy after self-expandable insertion. This study retrospectively compared results between surgery plus and stenting metastatic pyloric stenosis.Subjects comprised 26 patients who received or endoscopic stenosis April 2000 December 2007 in four Japanese hospitals. Patients were categorized into two groups: 15 (Surgery group); 11 (Stent...
Summary Background : The epidemiology and pathophysiology of non‐erosive gastro‐oesophageal reflux disease differs from erosive disease. There is a possibility that treatment requires different regimen/approach but it not yet acknowledged. Aim To investigate the efficacy famotidine omeprazole in disease, especially Patients methods A randomized, open‐label trial was conducted. Fifty‐four patients were assigned to with at dosage 20 mg twice daily; or omeprazole, once daily, for period 8...
We had previously reported that the administration of Gastrografin through a nasogastric tube (NGT-G) followed by long (LT) strategy could be novel standard treatment for adhesive small bowel obstruction (ASBO); however, long-term outcomes after initial improvement remain unknown. This study aimed to analyze first-line NGT-G.Enrolled patients with ASBO were randomly assigned receive LT or NGT-G between July 2016 and November 2018. Thereafter, cumulative surgery rate, recurrence overall...
Anti-epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors, which are molecular-targeted drugs used in cancer treatment, suspected to have analgesic effects on cancer-related pain. The relieving effect of EGFR inhibitors neuropathic pain has been described persist for approximately 20 days patients with colorectal cancer. Since the administration panitumumab, ananti-EGFR antibody, is repeated every 14 days, its should be maintained until next administration. To...
症例は65歳男性．C型肝炎に伴う肝細胞癌および右腎細胞癌に対し一期的に外科的切除術施行．その後，経過観察中にみつかった肝細胞癌の孤立性再発に対しラジオ波焼灼術にて治療するも，糖尿病に伴う慢性腎不全が徐々に進行し，透析導入を考慮するまで悪化した（血清クレアチニン値；5.39）．このころ，MRI検査で多発性肝癌の再発が明らかとなり透析導入は見送られ，血管造影下の治療も施行不可能となった．肝予備能がChild Aであったためソラフェニブを400 mg/日で投与開始した（腫瘍マーカー：AFP 3774 ng/ml，PIVKA-II 14995 mAU/ml）．投与後1週間前後にgrade 3の水様性下痢が出現し，200 mg/日に減量とし症状が安定したので外来フォローとなった．腫瘍マーカーは投与5カ月後には正常化し，MRI検査では多発する腫瘤像は縮小しPRと判断された．また造影エコーでも腫瘍部の血流は認めず効果は良好と判断された．特記すべきことはソラフェニブ投与後，血清クレアチニン値は徐々に低下し2013年3月現在，1.45まで改善し腫瘍マーカー正常で継続投与中である．